Active — Not RecruitingNot Applicable

the PHENOSAR Trial: Use of Antibiotics in Treatment of Sarcoidosis

Netherlands40 participantsStarted 2023-02-15

Plain-language summary

In this study it is investigated whether treatment with azithromycin in combination with doxycycline reduces the bacterial load of C. acnes in granulomatous tissue of patients with sarcoidosis and subsequently decreases the inflammatory activation measured by FDG uptake and serum biomarkers.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Biopsy proven sarcoidosis. * No treatment indication for the sarcoidosis * Inflammatory activity according to FDG-PET scan at baseline * SUVmax above 3 in the lung and/or above 5 in mediastinum/hili Exclusion Criteria: * Increased duration of QT interval (\>440ms for men and \>450ms for women) on ECG * Hearing deficits, as this is a possible side effect of azithromycin * Being pregnant or breastfeeding at time of inclusion

What they're measuring

SUVmax

Timeframe: 2 weeks

Trial details

NCT IDNCT05291468

SponsorSt. Antonius Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-04-26

View on ClinicalTrials.gov More Sarcoidosis, Pulmonary trials